

Elisabetta El Loggi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9568190/elisabetta-el-loggi-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

1,258
citations

16
h-index

34
g-index

34
ext. papers

1,462
ext. citations

4.8
avg. IF

3.33
L-index

#	Paper	IF	Citations
32	Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. <i>Gastroenterology</i> , 2010 , 138, 682-93, 693.e1-4	13.3	341
31	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. <i>Journal of Hepatology</i> , 2013 , 58, 225-33	13.4	154
30	Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. <i>Journal of Virology</i> , 2008 , 82, 10986-97	6.6	95
29	Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. <i>Gastroenterology</i> , 2012 , 143, 1576-1585.e4	13.3	85
28	Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. <i>Stem Cells</i> , 2006 , 24, 2817-25	5.8	72
27	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
26	HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. <i>PLoS Medicine</i> , 2007 , 4, e96	11.6	65
25	Peginterferon- α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012 , 56, 1239-46	13.4	58
24	Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. <i>Journal of Hepatology</i> , 2012 , 56, 579-85	13.4	52
23	Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. <i>Journal of Hepatology</i> , 2009 , 50, 625-30	13.4	36
22	Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". <i>Journal of Translational Medicine</i> , 2005 , 3, 20	8.5	33
21	Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. <i>Annals of Hepatology</i> , 2018 , 17, 64-75	3.1	26
20	Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. <i>PLoS ONE</i> , 2013 , 8, e65327	3.7	24
19	Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2013 , 56, 207-11	14.5	18
18	Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature. <i>World Journal of Gastroenterology</i> , 2016 , 22, 8010-6	5.6	16
17	Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. <i>PLoS ONE</i> , 2017 , 12, e0187755	3.7	14
16	Chronic hepatitis B: Are we close to a cure?. <i>Digestive and Liver Disease</i> , 2015 , 47, 836-41	3.3	13

15	Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 568-575	3.4	11
14	In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. <i>Cytokine</i> , 2004 , 26, 95-101	4	10
13	Vitamins in the treatment of chronic viral hepatitis. <i>British Journal of Nutrition</i> , 2011 , 105, 982-9	3.6	9
12	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , 2015 , 9, 586-93	8.8	6
11	Effect of liver transplantation on tuftsin activity and phagocytic activity of neutrophil granulocytes in patients with liver cirrhosis. <i>International Archives of Allergy and Immunology</i> , 2005 , 137, 258-62	3.7	6
10	Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. <i>Liver Transplantation</i> , 2008 , 14, 478-85	4.5	5
9	Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. <i>Liver International</i> , 2017 , 37, 54-61	7.9	3
8	Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. <i>World Journal of Gastroenterology</i> , 2009 , 15, 5946-52	5.6	3
7	SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. <i>Future Microbiology</i> , 2021 , 16, 1105-1133	2.9	3
6	The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection.. <i>Prostaglandins and Other Lipid Mediators</i> , 2022 , 106619	3.7	2
5	Gold standard assays for the monitoring of patients with chronic hepatitis C. <i>Future Virology</i> , 2018 , 13, 529-537	2.4	1
4	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. <i>Italian Journal of Medicine</i> , 2011 , 5, 82-89	0.5	1
3	Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. <i>BMJ Case Reports</i> , 2009 , 2009,	0.9	1
2	Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. <i>Annals of Hepatology</i> , 2014 , 13, 196-203	3.1	1
1	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. <i>Italian Journal of Medicine</i> , 2013 , 82-89	0.5	